KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...

I trained for a half-marathon in four months as a running beginner at 42. Here’s how it went

It turns out that doing hot yoga a few times a week and hiking at least once a week won’t make you a decent beginner runner. Month one was plagued by difficult quarter-mile runs and sore legs and ...